Threshold for defining PSMA-positivity prior to (177)Lu-PSMA therapy: a comparison of [(68)Ga]Ga-PSMA-11 and [(18)F]F-DCFPyL in metastatic prostate cancer

BACKGROUND: In 2022, the American Food and Drug Administration and the European Medicines Agency approved [(177)Lu]Lu-PSMA-617 (PLUVICTO™, Novartis AG, Basel, Switzerland) for radionuclide therapy with prostate-specific membrane antigen (PSMA) ligands in metastatic prostate cancer. Theranostics requ...

Descripción completa

Detalles Bibliográficos
Autores principales: Heilinger, Jan, Weindler, Jasmin, Roth, Katrin Sabine, Krapf, Philipp, Schomäcker, Klaus, Dietlein, Markus, Drzezga, Alexander, Kobe, Carsten
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10511392/
https://www.ncbi.nlm.nih.gov/pubmed/37731097
http://dx.doi.org/10.1186/s13550-023-01033-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10511392/
https://www.ncbi.nlm.nih.gov/pubmed/37731097
http://dx.doi.org/10.1186/s13550-023-01033-x

Ejemplares similares